Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1673
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2497
    -0.0014 (-0.11%)
     
  • Bitcoin GBP

    51,173.52
    -531.20 (-1.03%)
     
  • CMC Crypto 200

    1,334.43
    -62.10 (-4.45%)
     
  • S&P 500

    5,109.19
    +60.77 (+1.20%)
     
  • DOW

    38,291.95
    +206.15 (+0.54%)
     
  • CRUDE OIL

    83.75
    +0.18 (+0.22%)
     
  • GOLD FUTURES

    2,351.30
    +8.80 (+0.38%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Why Neurocrine Biosciences Shares Fell Nearly 10% Today

Why Neurocrine Biosciences Shares Fell Nearly 10% Today

Shares of biopharma Neurocrine Biosciences (NASDAQ: NBIX) were down 9.8% in Tuesday's late trading following a disappointing third-quarter report. For the three-month stretch ending in September, Neurocrine turned $296 million in revenue into an operating profit of $0.64 per share. On the basis of generally accepted accounting principles (GAAP), however, profits of only $0.23 per share left the market wanting more, and arguably concerned.